A novel elastin-like polypeptide drug carrier for cyclosporine A improves tear flow in a mouse model of Sjögren's syndrome

Guo, Hao; Lee, Changrim; Shah, Mihir; Janga, Srikanth Reddy; Edman, Maria C.; Klinngam, Wannita; Hamm‐Alvarez, Sarah F.; MacKay, J. Andrew

doi:10.1016/j.jconrel.2018.10.026

Cited by 27 publications

(16 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this research, we performed database analysis, in vitro and animal assays and found the potential link between CYPA expression and SOC progression. CYPA expression, similar to previous studies, was obviously correlated with clinical features of SOC patients, including tumor stage and lymphnode metastasis [33][34][35][36][37][38]. Our results are similar with previous studies indicating the important role of CYPA in tumorigenesis.…”

Section: Discussionsupporting

confidence: 91%

“…CYPA was first found as the target of cyclosporin A (CsA), an immunosuppressive drug, which has been used for the treatment of several tumors, including ovarian cancer [37]. Although the regulatory mechanism underlying CYPA promoting OC progression is still unclear, previous studies showed that CSA could bind to CYPA and thus increase the effects of chemotherapy [38].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

RETRACTED ARTICLE: CYPA promotes the progression and metastasis of serous ovarian cancer (SOC) in vitro and in vivo

Wang

Yue³

et al. 2019

J Ovarian Res

View full text Add to dashboard Cite

Ovarian cancer (OC) is a type of gynaecological malignancy with high mortality in females. Serous ovarian cancer (SOC) is a distinct subtype of OC with poor early diagnosis. Given the limitations of traditional therapies, such as chemotherapy, targeted treatment is therefore a promising therapy to improve the survival rate of SOC patients. Cyclophilin A (CYPA) is a member of Cyclophilin family and thought to participates in multiple cellular processes such as cell transduction and immune modulation. Recently, various of studies indicated that CYPA has critical impact on cancer progression. CYPA could regulate cell proliferation, invasion, and chemoresistance of multiple types of cancers. However, it is still unclear whether it could affect ovarian cancer. In this study, we demonstrated that CYPA was highly expressed in SOC tissues compared with adjacent tissues. Further, CYPA was significantly associated with clinical stage and lymphnode metastasis of SOC patients. Additionally, data indicated that knockdown of CYPA by its shRNA dramatically reduces migration and invasion capacity of SOC cells in vitro and blocks tumor metastasis in vivo. Our study investigates the involvement of CYPA in the progression and metastasis of SOC, and therefore provides CYPA as a promising therapeutic target for SOC treatment.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 99%

RETRACTED ARTICLE: CYPA promotes the progression and metastasis of serous ovarian cancer (SOC) in vitro and in vivo

Wang

Yue³

et al. 2019

J Ovarian Res

View full text Add to dashboard Cite

show abstract

“…The clearance of the fusion protein was determined to be 0.28 mL/hr, which is consistent with other reported clearance of high molecular weight ELPs. 13,14 The volume of distribution was calculated to be 1.92 mL, which is consistent with the expected volume of blood in these mice. Bioluminescence images of spleen, kidneys, and liver showed that α-CD99-A192 nanoworms still resided in those organs 96 hours post-injection and accumulated at a higher level in the liver as compared to the spleen and kidney (p ≤0.05) (Representative bioluminescence images and quantification Fig.…”

Section: Pk Profile Of α-Cd99-a192 Nanoworms Fits the Biexponential Decay Modelsupporting

confidence: 72%

Anti-CD99 scFv-ELP nanoworms for the treatment of acute myeloid leukemia

Vaikari

Park

Keossayan

et al. 2020

Nanomedicine: Nanotechnology, Biology and Medicine

Self Cite

View full text Add to dashboard Cite

CD99 is a transmembrane glycoprotein shown to be upregulated in various malignancies. We have previously reported CD99 to be highly upregulated and presents a viable therapeutic target in acute myeloid leukemia (AML). Currently, no therapy against CD99 is under clinical investigation. As a surface molecule, CD99 can be targeted with an antibody-based approach. Here, we have developed a new modality to target CD99 by engineering a fusion protein composed of a single-chain variable fragment antibody (anti-CD99 scFv) conjugated with a high molecular weight elastin-like polypeptide (ELP), A192: α-CD99-A192. This fusion protein assembles into multi-valent nanoworm with optimal physicochemical properties and favorable pharmacokinetic parameters (half-life ~16 hours). α-CD99-A192 nanoworms demonstrated excellent in vitro and in vivo anti-leukemic effects. α-CD99-A192 induced apoptotic cell death in AML cell lines and primary blasts and prolonged overall survival of AML xenograft mouse model.

show abstract

“…Despite being a very popular line of treatment for patients with DED, optimal doses and the optimal duration of treatment are still debatable. Furthermore, adverse effects such as foreign body sensation, conjunctival hyperemia, and epiphora can accompany treatment with this medicine [ 46 , 47 , 48 ]. Another alternative could be lifitegrast.…”

Section: Ocular Pathologies Related To Oxidative Stress and Inflammentioning

confidence: 99%

Ocular Delivery of Polyphenols: Meeting the Unmet Needs

2021

View full text Add to dashboard Cite

Nature has become one of the main sources of exploration for researchers that search for new potential molecules to be used in therapy. Polyphenols are emerging as a class of compounds that have attracted the attention of pharmaceutical and biomedical scientists. Thanks to their structural peculiarities, polyphenolic compounds are characterized as good scavengers of free radical species. This, among other medicinal effects, permits them to interfere with different molecular pathways that are involved in the inflammatory process. Unfortunately, many compounds of this class possess low solubility in aqueous solvents and low stability. Ocular pathologies are spread worldwide. It is estimated that every individual at least once in their lifetime experiences some kind of eye disorder. Oxidative stress or inflammatory processes are the basic etiological mechanisms of many ocular pathologies. A variety of polyphenolic compounds have been proved to be efficient in suppressing some of the indicators of these pathologies in in vitro and in vivo models. Further application of polyphenolic compounds in ocular therapy lacks an adequate formulation approach. Therefore, more emphasis should be put in advanced delivery strategies that will overcome the limits of the delivery site as well as the ones related to the polyphenols in use. This review analyzes different drug delivery strategies that are employed for the formulation of polyphenolic compounds when used to treat ocular pathologies related to oxidative stress and inflammation.

show abstract

A novel elastin-like polypeptide drug carrier for cyclosporine A improves tear flow in a mouse model of Sjögren's syndrome

Cited by 27 publications

References 63 publications

RETRACTED ARTICLE: CYPA promotes the progression and metastasis of serous ovarian cancer (SOC) in vitro and in vivo

RETRACTED ARTICLE: CYPA promotes the progression and metastasis of serous ovarian cancer (SOC) in vitro and in vivo

Anti-CD99 scFv-ELP nanoworms for the treatment of acute myeloid leukemia

Ocular Delivery of Polyphenols: Meeting the Unmet Needs

Contact Info

Product

Resources

About